RecruitingCLLChronic Lymphocytic Leukemia

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Sponsor: BeOne Medicines

You may qualify if…

✓ 1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
✓ 2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
✓ 3. Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
✓ 4. Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
✓ 5. Adequate liver function
✓ 6. Adequate blood clotting function

You may not qualify if…

✕ 1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
✕ 2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months
✕ 3. Known central nervous system involvement
✕ 4. Prior exposure to any BTK protein degraders
✕ 5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
✕ 6. Clinically significant cardiovascular disease
✕ NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.